Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
BUSINESS - CYSTIC FIBROSIS

Reducing lung infection and inflammation due to Cystic Fibrosis

 

BY OUR PHARMA  CORRESPONDENT

BOTHELL, Wash., July 5 /PRNewswire-FirstCall/ -- Helix BioMedix (BULLETIN BOARD: HXBM.OB) , a developer of synthetic bioactive peptides, today announced that research published in the July 2005 issue of Antimicrobial Agents and Chemotherapy titled "Antimicrobial Peptide Therapeutics for Cystic Fibrosis" has shown that small bioactive peptides have the potential to attack two of the components responsible for the progression of lung damage in Cystic Fibrosis disease: infection and inflammation.

The research was conducted by Lijuan Zhang, Jody Parente and Scott M. Harris of Helix BioMedix, in conjunction with Professor Donald E. Woods of the Department of Microbiology and Infectious Diseases, University of Calgary Health Sciences Centre, Professor Robert E. W. Hancock of the Department of Microbiology and Immunology, University of British Columbia and Timothy J. Falla of Helix BioMedix.

"We are excited about the findings of this research," commented Timothy J. Falla, Vice President and Chief Scientific Officer of Helix BioMedix. "Our peptides have proven to be fast acting, bactericidal and active against multidrug-resistant bacteria. In addition, certain peptides seem to exhibit anti-inflammatory, immunomodulatory, and wound healing activities in addition to antimicrobial activity. This makes them excellent candidates to help halt two of the components that are responsible for the progression of lung disease in cystic fibrosis patients."

R. Stephen Beatty, President and CEO of Helix BioMedix, added, "Growing resistance to antibiotics for the treatment of infection and inflammation in the lungs of cystic fibrosis patients is a major reason for loss of pulmonary function and is a significant contributing factor to the mortality of the disease. This is just another example of the broad range of pharmaceutical applications for which our proprietary peptides have shown early-stage promise."

In this study, 150 peptides were screened for activity against cystic fibrosis (CF) pathogens such as P. aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Staphylococcus aureus in the presence of factors that mimic the physiological environment of the CF lung. Peptides with good anti-inflammatory as well as antimicrobial activity were then tested in animal models for in vivo efficacy. Peptides were delivered to the lung via nebulization in three daily doses following infection, resulting in an estimated lung delivery of 10 to 15 ug per dose. The control group was treated with saline. The data suggests that the lead peptides, HBCM2, HBCM3, HBCPa-2 and HB71 significantly reduced the numbers of viable bacteria in the infected lungs of rats as well as demonstrating good anti-inflammatory activity in mice. The in vitro antimicrobial coverage of most peptides was superior to most conventional antibiotics. In addition to bactericidal activity towards multiple microorganisms, some peptides also possessed potent anti-gram-positive and anti-Candida activity, an advantage, since those pathogens can be present in the CF lung, and other antibiotics used in CF therapy, such as tobramycin, often lack useful gram-positive and fungal coverage.

According to the Cystic Fibrosis Foundation CF, a genetic disease, affects approximately 30,000 children and adults in the United States and more than 10 million Americans are unknowing, symptomless carriers of the defective CF gene. The major morbidity and mortality in CF are caused by the progressive loss of pulmonary function that results from a cycle of inflammation and infection. The main method of combating lung infections in CF patients is antibiotic treatment. With the increasing life expectancy of such patients due to improved care, more courses of antibiotics are used for longer terms and at higher doses, with the adverse consequence of increasing antimicrobial resistance. By 18 years of age, 80% of patients become chronically infected with Pseudomonas aeruginosa. P. aeruginosa is a difficult organism to treat in most human infections due to its high intrinsic antibiotic resistance. In addition, during the past decade, no new antibiotics have been approved for the treatment of pathogens in the CF patient lung. The observation of lack of potential resistance and/or cross-resistance makes antimicrobial peptides extremely interesting candidates for use in CF therapy.


Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

Viruses may help cure cancer by killing cancer cells

New product relieves tooth pain resulting from dental sensitivity 

Cervical Cancer detector may improve on Pap Smears

Dietary supplement capsule by Liqing banned in US

Cold Stone Creamery cake batter ice-creams recalled

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA approval for PEPFAR

Gates Foundation donates for a good cause

Paxil CR resupply in US pharmacies announced by GlaxoSmithKline

Viagra users not at risk of blindness: Pfizer

Stem cell research gets boost from Li Ka-shing

BiDil heart failure drug for black patients approved

Restless leg syndrome could be messing up your sleep

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

German Remedies launches Fludara Oral

Ranbaxy acquires generic product portfolio from Efarmes

Sandoz files seven ANDAs of drugs going off-patent

Elder Pharma plans unit, brand acquisition

Novasite Pharma buys PsyCheNomicS

Chemokine gets US patent for novel cancer drug

Roche gets USFDA approval for oral Xeloda

Nectar Lifesciences plans Rs 90 crore IPO 

Glaxo inks co-promotion pact with Eisai for Paritec

Early Intervention required to Prevent Diabetes

AIDS drug ahoy!

Novartis launches AMD patient counselling programme

Nanobac Life Sciences, UCSF to study kidney stones 

Surface Logix commences phase I trial for PDE-5 inhibitor

Temasek sets up $112 million pharma JV

Contraceptive from Neem, courtesy DRDO  

US FDA to source anti-HIV drugs from Indian firms  

Chemists boycott Glaxo, Novartis products  

Maharashtra phases out nerve tissue-based rabies vaccine  

Last long, really long - new sex drug soon  

Johnson and Johnson demonstrates coronary stent safety

Novartis has better breast cancer treatment

Pfizer's investigational drug reduces tumor growth

New labeling for beta-blocker Coreg 

Glaxo applies for FDA approval for Flaurix

Investigational drug for Acute Bipolar Mania And Schizophrenia

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us